X
<
sp-500-1
US Markets Had a Mixed Performance on December 14

The S&P 500 started this week on a stronger note. Despite a strong start, the market lost momentum as the week progressed and fell on Thursday.

KSS-Price-1
Can Kohl’s Stock Pick Up Some Momentum?

Kohl’s (KSS) stock price has risen 1.8% on a YTD (year-to-date) basis as of December 12.

Part-1-EPS-Guidance-1-1
Honeywell Stock Gains on Fiscal 2018 Guidance

On December 13, 2017, Honeywell International (HON) provided its earnings guidance for 2018. Its guidance indicates an EPS of $7.55–$7.80 for fiscal 2018.

TGT-Digital-1
Target Ups Its Delivery Game amid Increased Competition

Target (TGT) recently announced the acquisition of Shipt, one of the leading online platforms that provides same-day delivery.

RECENT Healthcare RESEARCH

intralipid-iv-emulsion-1-1
Investor Update: Recent Developments at Baxter International

On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.

Chart-01-EPS-1
What to Expect from Johnson & Johnson’s 3Q17 Earnings

Johnson & Johnson (JNJ) is set to release its 3Q17 earnings on October 17. Analysts expect JNJ’s 3Q17 revenues to rise ~8.3% to ~$19.3 billion compared to ~$17.8 billion for 3Q16.

Graph-1-2-1
Sanofi: Should We Pay Attention to It in 2017?

Of the three analysts covering Sanofi in October 2017, two have rated the stock a “strong buy,” and one has rated it a “hold.”

projections
Edwards Lifesciences: 3Q17 Earnings Preview

Edwards Lifesciences (EW) has scheduled its 3Q17 earnings release for October 24, 2017. This leading player in the artificial heart valves market has been gaining momentum and trading near its 52-week high.

Analysts-Rating-2-1
Eli Lilly in the Spotlight: Key Potential Growth Drivers

So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”

RECOMMENDATIONS
Why Wall Street Is Bullish on JNJ Stock ahead of 3Q17 Results

Johnson & Johnson (JNJ) will announce its 3Q17 earnings results on October 17, 2017.

recommendations
What to Expect from Intuitive Surgical's 3Q17 Earnings

Intuitive Surgical (ISRG) is set to announce its 3Q17 earnings results on October 19, 2017. Over the past few weeks, ISRG stock has risen to new highs.

recommendations
Abbott Laboratories 3Q17 Earnings: What's Expected

On October 18, 2017, Abbott Laboratories will release its 3Q17 earnings results. Abbott stock was trading at its 52-week high of $55.4 on October 10.

Analysts-Rating-1
A Look at Amgen's Long-Term Growth Drivers

Of the 24 analysts tracking Amgen (AMGN) in October 2017, ~42% of the analysts recommended a “buy” rating, and the rest suggested a ”hold.” On October 5, Amgen had a consensus 12-month target price of ~$189.35.

Graph-3-2-1
An Investor's Guide to United Therapeutics in 2017

In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

Analysts-Rating-Biogen-1
An Update on Biogen after 1H17

Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn’t receive any “sell” or “strong sell” ratings.

stock-price-1
Can Intuitive Surgical Sustain Its Current Stock Rally?

Intuitive Surgical (ISRG), the leader in minimally invasive robotics surgery, has seen tremendous growth lately. It was trading at its 52-week high of $1,094.55 on October 5, 2017.

recommendations
Where BD Stands after Its Latest Developments

Of the 15 firms tracking BD, ~67% of analysts have recommended a “buy” for BD—of which 70% have given a “strong buy” recommendation.

Graph-1-1
Should We Be Interested in Cardinal Health in 2017?

Cardinal Health (CAH) reported revenues of $130.0 billion for fiscal 2017, which is a YoY (year-over-year) rise of 7.0%.

Analysts-Ratings-2-1
Who's Watching Exelixis Now?

Ten analysts were covering Exelixis in October 2017. One analyst suggested a “strong buy,” and five analysts suggested a “buy” rating.

Analysts-Ratings-1
Who's Watching Alexion Now?

In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals’ (ALXN) Soliris.

1
How Rite Aid Performed in 2Q17

Rite Aid (RAD) reported results for 2Q17 on Thursday, September 28, 2017. The company reported a loss of one cent per share on total sales of $7.7 billion.

Chart-01-Dev-2-1
GlaxoSmithKline’s Latest Developments and Valuation

On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.

stock-price-4-1
Abbott Stock Rides High on Recent Product Approvals

Abbott Laboratories (ABT) was trading at its 52-week high of $54.75 on September 29, 2017.

Graph-23-1
Medtronic: Poised to Leverage Cardiac Space in Fiscal 2018

Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.

X

Please select a profession that best describes you: